Radiolabeled anti-claudin 4 and anti-prostate stem cell antigen: Initial imaging in experimental models of pancreatic cancer

Molecular Imaging

Volumn 6, Issue 2, 2007, Pages 131-139

  Foss, Catherine A ^b   Fox, James J ^b   Feldmann, Georg ^b   Maitra, Anirban ^b   Iacobuzio Donohue, Christine ^b   Kern, Scott E ^b   Hruban, Ralph ^b   Pomper, Martin G ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CANCER XENOGRAFTS; PROSTATE STEM CELL ANTIGEN; RADIOLABELED;

ANTIBODIES; CELLS; FLUORESCENCE; GAMMA RAYS; IMMUNOLOGY; IODINE; ONCOLOGY; POSITRON EMISSION TOMOGRAPHY;

IMAGING TECHNIQUES;

CLAUDIN 4; EPITOPE; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; PSCA PROTEIN, HUMAN; RADIOACTIVE IODINE; TUMOR ANTIGEN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; CANCER TRANSPLANTATION; CHEMISTRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; IMMUNOLOGY; METHODOLOGY; MOUSE; PANCREAS TUMOR; RADIOIMMUNOASSAY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; EPITOPES; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IODINE RADIOISOTOPES; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MICE; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; RADIOIMMUNODETECTION;

EID: 34250780578     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.2310/7290.2007.00010     Document Type: Article

References (31)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Pitt HA, Nakeeb A, Abrams RA, et al. Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival. Ann Surg 1995;221;788-97; discussion 797-88.
3. Schafer M, Mullhaupt B, Clavien PA. Evidence-based pancreatic head resection for pancreatic cancer and chronic pancreatitis. Ann Surg 2002;236:137-48.
4. Doi R, Fujimoto K, Kobayashi H, Imamura M. Impact of reconstruction methods on outcome of pancreatoduodenectomy in pancreatic cancer patients. World J Surg 2005;29:500-4.
5. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005;46 Suppl 1:62S-6S.
6. Zervos EE, Rosemurgy AS, Al-Saif O, Durkin AJ. Surgical management of early-stage pancreatic cancer. Cancer Control 2004;11:23-31.
7. Argani P, Rosty C, Reiter RE, et al. Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res 2001;61:4320-4.
8. Iacobuzio-Donahue CA, Ashfaq R, Maitra A, et al. Highly expressed genes in pancreatic ductal adenocardnomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res 2003;63:8614-22.
9. Nichols LS, Ashfaq R, Iacobuzio-Donahue CA. Claudin 4 protein expression in primary and metastatic pancreatic cancer: support for use as a therapeutic target. Am J Clin Pathol 2004;121:226-30.
10. Gu Z, Thomas G, Yamashiro J, et al. Prostate stem cell antigen (PSCA) expression increases with high Gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 2000;19:1288-96.
11. McCarthy DM, Maitra A, Argani P, et al. Novel markers of pancreatic adenocarcinoma in fine-needle aspiration: mesothelin and prostate stem cell antigen labeling increases accuracy in cytologically borderline cases. Appl Immunohistochem Mol Morphol 2003;11:238-43.
12. Reiter RE, Gu Z, Watabe T, et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A 1998;95:1735-40.
13. Schniewind B, Christgen M, Kurdow R, et al. Resistance of pancreatic cancer to gemdtabine treatment is dependent on mitochondria-mediated apoptosis. Int J Cancer 2004;109:182-8.
14. Bruns CJ, Harbison MT, Kuniyasu H, et al. In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia 1999;1:50-62.
15. Smith-Jones PM, Vallabhajosula S, Navarro V, et al. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nucl Med 2003;44:610-7.
16. Resnick MB, Gavilanez M, Newton E, et al. Claudin expression in gastric adenocarcinomas: a tissue microarray study with prognostic correlation. Hum Pathol 2005;36:886-92.
17. Alazraki N. Imaging of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography. J Gastrointest Surg 2002;6:136-8.
18. Nishiyama Y, Yamamoto Y, Monden T, et al. Evaluation of delayed additional FDG PET imaging in patients with pancreatic tumour. Nucl Med Commun 2005;26:895-901.
19. Bean MJ, Fishman EK. Focal FDG uptake in a pancreatic lipoma mimicking malignancy. J Comput Assist Tomogr 2005;29:475-6.
20. Achilefu S, Srinivasan A, Schmidt MA, et al. Novel bioactive and stable neurotensin peptide analogues capable of delivering radiopharmaceuticals and molecular beacons to tumors. J Med Chem 2003;46:3403-11.
21. Anderson CJ, Dehdashti F, Cutler PD, et al. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nucl Med 2001;42:213-21.
22. Schuhmacher J, Zhang H, Doll J, et al. GRP receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a 68Ga-labeled bombesin(6-14) analog. J Nucl Med 2005;46:691-9.
23. Cardillo TM, Karacay H, Goldenberg DM, et al. Improved targeting of pancreatic cancer: experimental studies of a new bispecific antibody, pretargeting enhancement system for immunoscintigraphy. Clin Cancer Res 2004;10:3552-61.
24. Moore A, Medarova Z, Potthast A, Dai G. In vivo targeting of underglycosylated MUC-1 tumor antigen using a multimodal imaging probe. Cancer Res 2004;64:1821-7.
25. Chakrabarti A, Aruva MR, Sajankila SP, et al. Synthesis of novel peptide nucleic acid-peptide chimera for non-invasive imaging of cancer. Nucleosides Nucleotides Nucleic Acids 2005;24:409-14.
26. Michl P, Buchholz M, Rolke M, et al. Claudin-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin. Gastroenterology 2001;121:678-84.
27. Wente MN, Jain A, Kono E, et al. Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancer. Pancreas 2005;31:119-25.
28. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med 2003;44:1962-9.
29. Todorovska A, Roovers RC, Dolezal O, et al. Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J Immunol Methods 2001;248:47-66.
30. Robinson MK, Doss M, Shaller C, et al. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res 2005;65:1471-8.
31. Gonzalez Trotter DE, Manjeshwar RM, Doss M, et al. Quantitation of small-animal (124)I activity distributions using a clinical PET/ CT scanner. J Nucl Med 2004;45:1237-44.